MARKET

SAGE

SAGE

SAGE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

56.38
+0.69
+1.24%
Closed 17:40 06/23 EDT
OPEN
55.78
PREV CLOSE
55.69
HIGH
57.26
LOW
55.25
VOLUME
685.12K
TURNOVER
--
52 WEEK HIGH
98.39
52 WEEK LOW
40.35
MARKET CAP
3.30B
P/E (TTM)
5.10
1D
5D
1M
3M
1Y
5Y
Top Healthcare Stocks for July 2021
These are the healthcare stocks with the best value, fastest growth, and most momentum for July 2021.
Investopedia · 15h ago
CVS and Rite Aid get price target cuts, Sage target trimmed on depression drug data, and more in analyst action
Olemedia/E+ via Getty Images Decline in vaccines means PT changes for drug store chains The number of vaccines administered at drug stores has plummeted, leading Deutsche Bank to rethink its
Seekingalpha · 1d ago
Mizuho Securities Adjusts Sage Therapeutics' Price Target to $60 From $77, Maintains Neutral Rating
MT Newswires · 2d ago
Insiders at Sage Therapeutics (SAGE) Make Significant purchases of Stock
MT Newswires · 5d ago
Sage Therapeutics: Should You Buy This Beaten-Down Stock? Analyst Weighs In
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only a buck or two, while getting a biotech company wrong can hurt a lot more than that. Case in point: Sag...
TipRanks · 6d ago
Biogen Discontinues Tau Antibody Program For Alzheimer's After Mid-Stage Study Flops
Biogen Inc (NASDAQ: BIIB) has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, of which one has just been canned.
Benzinga · 6d ago
Insider Trends: Insider Purchase of Sage Therapeutics Stock Extends 90-Day Positive Trend
MT Newswires · 6d ago
Insider Trends: Sage Therapeutics Insider Awarded Stock, Exercises Derivative Security, Pays Taxes with Portion
MT Newswires · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SAGE. Analyze the recent business situations of SAGE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SAGE stock price target is 92.53 with a high estimate of 189.00 and a low estimate of 60.00.
EPS
Institutional Holdings
Institutions: 427
Institutional Holdings: 62.98M
% Owned: 107.70%
Shares Outstanding: 58.48M
TypeInstitutionsShares
Increased
77
5.07M
New
55
769.45K
Decreased
84
4.53M
Sold Out
41
1.71M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.36%
Pharmaceuticals & Medical Research
-0.51%
Key Executives
Non-Executive Chairman/Independent Director
Kevin Starr
President/Chief Executive Officer/Director
Barry Greene
Chief Financial Officer/Treasurer
Kimi Iguchi
Senior Vice President/General Counsel/Secretary
Anne Cook
Chief Scientific Officer
Albert Robichaud
Other/Director
Jeffrey Jonas
Other
Stephen Kanes
Independent Director
Elizabeth Barrett
Independent Director
Michael Cola
Independent Director
James Frates
Independent Director
Geno Germano
Independent Director
George Golumbeski
Independent Director
Steven Paul
No Data
  • All
  • Financials
  • Insiders
More
About SAGE
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Webull offers kinds of SAGE Therapeutics Inc stock information, including NASDAQ:SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAGE stock methods without spending real money on the virtual paper trading platform.